ACCC association of cancer care centers

FDA Approves Atezolizumab for Small Cell Lung Cancer

On March 19, the FDA approved atezolizumab (Tecentriq®, Genentech) in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Read the Roche press release here.
Read the FDA press release here.
Download the Tecentriq ES-SCLC Day 1 Letter here.

Posted 3/19/2019

Related Content

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

May 12, 2026

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer

May 8, 2026

FDA Approves Relacorilant With Nab-paclitaxel for Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

March 26, 2026

FDA Approves Nivolumab With Chemotherapy for Previously Untreated Hodgkin Lymphoma

March 26, 2026

FDA Approves Teclistamab in Combination With Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

March 6, 2026

FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-squamous Non-small Cell Lung Cancer

March 4, 2026

FDA Grants Traditional Approval to Encorafenib for Metastatic Colorectal Cancer With a BRAF V600E Mutation

March 4, 2026

FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

February 20, 2026

Upcoming Events

ACCC Oncology Reimbursement Meeting | Providence

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,
Register Now!
Virtual ORM | Winter 2026

Virtual ORM | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
Register Now!
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington
Register Now!